Literature DB >> 6433759

Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis.

J R Chapman, P J Charles, P J Venables, P J Thompson, P L Haslam, R N Maini, M E Turner Warwick.   

Abstract

Antinuclear antibodies (ANA) were studied in 122 patients with cryptogenic fibrosing alveolitis (CFA) and compared with age- and sex-matched control subjects. Fluorescent ANA were detected in 32% of the patients and showed a correlation with the presence of a systemic connective tissue disease; ANA were present in 6% of the control subjects, 21% of the patients with CFA alone, and 46% of those with CFA and an associated connective tissue disease. Antibodies to the defined nuclear antigens: deoxyribonucleic acid (DNA), nuclear ribonucleoprotein (nRNP), the Sm antigen, and Sjögren's syndrome A and B antigens (SS-A and SS-B) were examined to establish whether their presence was diagnostic of the associated diseases. Antibodies to DNA and Sm antigens identified 3 patients with CFA and systemic lupus erythematosus. The frequency of antibodies to SS-A and SS-B did not differ from that in control subjects. Antibodies to nRNP, detected in 15 (12%) of the patients (at a high titer in 5), were associated with females, the presence of Raynaud's phenomenon, and rheumatoid factor in the serum. However, despite the detection of these antibodies, none of these patients met fully the proposed criteria for the diagnosis of mixed connective tissue disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433759     DOI: 10.1164/arrd.1984.130.3.439

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  23 in total

Review 1.  In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?

Authors:  M Turner-Warwick
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Some connective tissue disorders of the lung.

Authors:  M Turner-Warwick
Journal:  Postgrad Med J       Date:  1988-07       Impact factor: 2.401

3.  Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes.

Authors:  R Misra; P J Venables; C Plater-Zyberk; P F Watkins; R N Maini
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

4.  Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Authors:  R Meliconi; E Lalli; R M Borzì; C Sturani; V Galavotti; G Gunella; R Miniero; A Facchini; G Gasbarrini
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

5.  Expression of class II MHC antigens on alveolar epithelium in fibrosing alveolitis.

Authors:  C G Kallenberg; B M Schilizzi; F Beaumont; S Poppema; L De Leij; T H The
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

6.  Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population.

Authors:  A O Adebajo; P Charles; R N Maini; B L Hazleman
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Characterisation of non-histone nuclear proteins cross reactive with purified rheumatoid factors.

Authors:  J C Mason; P J Venables; P R Smith; R N Maini
Journal:  Ann Rheum Dis       Date:  1985-05       Impact factor: 19.103

8.  Serological profile of rheumatoid arthritis in west Africa.

Authors:  A O Adebajo; P J Charles; B L Hazleman; R N Maini
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

9.  Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia.

Authors:  Bo Hyoung Kang; Jin Kyeong Park; Jae Hyung Roh; Jin Woo Song; Chang Keun Lee; Miyoung Kim; Se Jin Jang; Thomas V Colby; Dong Soon Kim
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

10.  Expression of class II major histocompatibility complex antigens on alveolar epithelium in interstitial lung disease: relevance to pathogenesis of idiopathic pulmonary fibrosis.

Authors:  C G Kallenberg; B M Schilizzi; F Beaumont; L De Leij; S Poppema; T H The
Journal:  J Clin Pathol       Date:  1987-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.